Naveris
Waltham, US · Founded 2017 · Delaware corporation · 1 known investors
Naveris is a molecular diagnostics company that develops liquid biopsy blood tests, including its NavDx test, to detect and monitor HPV-driven cancers such as head & neck and anal cancers. Its tests analyze cancer-associated HPV DNA in blood plasma to support earlier detection of recurrence, treatment response assessment, and confirmatory diagnosis for oncology providers and patients.
Founders & leadership
JM
James McNallyExecutive
PG
Piyush GuptaNamed on SEC filing
Board
AS
Anne StoneBoard director
FC
Francis CrispinoBoard director
PG
Philip Grahame HaydonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$33.6M disclosed across 3 rounds · 2019–2024
▶$17.5MraisedJul 2024 · 5 investors · BiotechnologyRule 506(b)
▶$17.5MraisedJul 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James McNallyExecutive Officer, Director
- Anne StoneDirector
- Francis CrispinoDirector
- Piyush GuptaExecutive Officer, Director
- Offering amount
- $27.2M
- Amount sold
- $17.5M
- Sales commissions
- $1.8M
- Placement agents
- Cowen and Company, LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.4MraisedMar 2020 · 21 investors · BiotechnologyRule 506(b)
▶$15.4MraisedMar 2020 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piyush GuptaExecutive Officer, Director
- Philip StephensExecutive Officer
- Barry BergerDirector
- Sophie KornowskiDirector
- Offering amount
- $17M
- Amount sold
- $15.4M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$650KraisedSep 2019 · 3 investors · Other TechnologyRule 506(b)
▶$650KraisedSep 2019 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Philip Grahame HaydonDirector
- Piyush GuptaExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $650K
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapLabcorp26 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
Alumis25 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Companies competing with Naveris for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Naveris do?
- Naveris is a molecular diagnostics company that develops liquid biopsy blood tests, including its NavDx test, to detect and monitor HPV-driven cancers such as head & neck and anal cancers. Its tests analyze cancer-associated HPV DNA in blood plasma to support earlier detection of recurrence, treatment response assessment, and confirmatory diagnosis for oncology providers and patients.
- Who are Naveris's investors?
- Naveris's investors include Gurnet Point Capital.
- How much funding has Naveris raised?
- Naveris has disclosed $33.6M raised across 3 rounds.
- Where is Naveris headquartered?
- Naveris is headquartered in Waltham, US.